Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a multicenter placebo-controlled study, patiromer, a nonabsorbable potassium binder, led to a reduction in serum potassium levels in patients with chronic kidney disease and hyperkalemia who were receiving renin–angiotensin–aldosterone system (RAAS) inhibitors.
Hyperkalemia is associated with life-threatening cardiac arrhythmias and increased...
Alternative Titles
Full title
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1645924067
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1645924067
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1410853
